References | Title | Number of participants and age | Type of immunotherapy (intervention vs. comparator) | Duration of treatment | Author results and conclusions |
---|---|---|---|---|---|
Valovirta et al. [27] | Results from the 5-year SQ grass sublingual immunotherapy tablet asthma prevention (GAP) trial in children with grass pollen allergy | 812 (5–12 years) | SLIT with Phleum pretense grass vs. placebo | 5 years (3 years treatment and 2 years follow-up) | Treatment with the SQ grass sublingual immunotherapy tablet significantly reduced the risk of experiencing asthma symptoms or using asthma medication (odds ratio = .66, P < .036) and the use of allergic rhinoconjunctivitis pharmacotherapy (27% less, P < .001) |
Durham et al. [29] | Sublingual immunotherapy with once-daily grass allergen tablets: A randomized controlled trial in seasonal allergic rhinoconjunctivitis | 855 (18–65 years) | SLIT with Phleum pretense grass vs. placebo | 18 weeks | Moderate reductions of rhinoconjunctivitis symptoms (16%) and medications use (28%). Significantly better rhinoconjunctivitis quality of life scores (P = .006) and an increased number of well days (P = .041) |
Ibañez et al. [30] | Safety of specific sublingual immunotherapy with SQ standardized grass allergen tablets in children | 60 (5–12 years) | SLIT with Phleum pretense grass vs. placebo | 1 February 2006 to 3 May 2006 | Local reactions were reported at intervention group. The majority of these were local reactions in the mouth or throat and were mostly mild (71%) to moderate (27%) in severity and resolved within days. Two actively treated subjects withdrew from the study: one subject due to four adverse events (moderate eye pruritus, moderate pharyngolaryngeal pain, moderate non-cardiac chest pain and moderate dysphagia) and one subject due to a serious adverse event (asthmatic attack). The subjects recovered completely from the events. SLIT was in general tolerated |
Didier et al. [32] | Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis | 628 (18–45 years) | Standardized 5-grass pollen extract (SLIT) vs. placebo | 16 December 2004 to 5 September 2005) | Significantly reduction of rhinoconjunctivitis total score (3.58 ± 3.0, P = .0001; and 3.74 ± 3.1, P = .0006) Compared with placebo (4.93 ± 3.2). The efficacy and safety of sublingual immunotherapy with grass tablets was confirmed |
Didier et al. [33] | Sustained 3-year efficacy of pre- and coseasonal 5-grass-pollen sublingual immunotherapy tablets in patients with grass pollen- induced rhinoconjunctivitis | 633 (18–50 years) | 5-grass pollen tablet (Oralair) vs. placebo | 5 years (3-season treatment and 2-year follow-up phases) | The mean symptom score was reduced by 36% and 34.5% at season 3 in the 2 and 4-months pre and coseasonal active treatment groups compared with placebo group (P < .0001 for both). Reductions were observed in total symptom scores and the medication score, with a marked improvement in quality of life for active groups compared with placebo |
Lozano et al. [34] | Assessing the Efficacy of Immunotherapy with a Glutaraldehyde-Modified House Dust Mite Extract in Children by Monitoring Changes in Clinical Parameters and Inflammatory Markers in Exhaled Breath | 43 (6–14 years) | SIT group (8 μg/ml of Der p1 and 30 μg/ml of Der p2) and treatment group (control group) | Between 2009 and 2011 | The SIT group presented with an improvement in asthma classification, a reduction in maintenance drug therapy and improved scores on the quality of-life questionnaire |
Ferrés et al. [35] | Efficacy of high-dose sublingual immunotherapy in children allergic to house dust mites in real-life clinical practice | 78 (6–18 years) | Retrospective, observational, monocentre study. Medical records of patients who received a standardized Dermatophagoides pteronyssinus + Dermatophagoides farinae extract (300 IR/ml) were reviewed | Between 2001 and 2008 | Patient evaluation of allergy severity revealed a highly significantly improvement between baseline and 6 months (P < .001). This improvement was maintained throughout the 4-year follow-up period. The use of medications was significantly reduced in the first 6 months (4.6 ± 2.5 points at baseline vs. .8 ± 1.6 points at 6 months visit, P < .001) and remained very low until the end of follow-up |
Mosbech et al. [40] | Standardized quality (SQ) house dust mite sublingual immunotherapy tablet (ALK) reduces inhaled corticosteroid use while maintaining asthma control: A randomized, double-blind, placebo-controlled trial | 604 (14 years or older) | SIT with standardized extracts of Dermatophagoides pteronyssinus and Dermatophagoides farinae vs. placebo | 12 months | Mean difference between 6 SQ-HDM and placebo in the reduction in daily ICS (P = .004). The most common adverse events were local reactions in the mouth |
Nolte et al. [41] | Efficacy of house dust mite sublingual immunotherapy tablet in North American adolescents and adults in a randomized placebo-controlled trial | 1482 (12 years or older) | SLIT group (tablets with 12 SQ HDM dose) and placebo group | January 2013 to April 2015 | Improvement In the total combined rhinitis score by 17% in the SIT group vs. placebo (P = .001). It was well tolerated and improved HDM-induced rhinitis symptoms |